{"nctId":"NCT02043132","briefTitle":"Tranexamic Acid in Reverse Total Shoulder Arthroplasty","startDateStruct":{"date":"2013-09"},"conditions":["Shoulder Joint Disease","Complications; Arthroplasty","Intraoperative Complications","Blood Loss, Surgical"],"count":116,"armGroups":[{"label":"Tranexamic acid","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Tranexamic Acid"]},{"label":"Normal Saline","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Tranexamic Acid","otherNames":["TXA","Antifibrinolytic"]},{"name":"Placebo","otherNames":["Normal Saline"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Patients undergoing scheduled primary reverse total shoulder arthroplasty performed by J. Michael Wiater, MD.\n2. Patients age 18 and older\n\nExclusion Criteria:\n\n1. Pregnant\\* or breast-feeding women\n2. Allergy to tranexamic acid\n3. Acquired disturbances of color vision\n4. Use of estrogen containing medications (i.e. oral contraceptive pills)\n5. Hormone replacement therapy\n6. Preoperative anemia \\[Hemoglobin (Hb) \\< 11g/dL in females, Hb \\< 12 g/dL in males\\]\n7. Refusal of blood products\n8. Preoperative use of anticoagulant therapy within 5 days prior to surgery\n\n   1. Coumadin\n   2. Heparin\n   3. Low molecular weight heparin\n   4. Factor Xa inhibitors\n9. Thrombin inhibitors\n10. Coagulopathy\n11. Thrombophilia\n12. Antithrombin deficiency\n13. Factor V Leiden\n14. Antiphospholipid Syndrome\n15. Protein C and S deficiency\n16. History of heparin induced thrombocytopenia\n17. Sickle cell anemia\n18. Myeloproliferative disorders\n19. Platelet \\< 150,00 mm3\n20. International Normalized Ratio (INR) \\> 1.4\n21. Partial Thromboplastin Time (PTT) \\> 1.4 times normal\n22. A history of arterial or venous thromboembolism\n23. Cerebral Vascular Accident\n24. Deep Vein Thrombosis\n25. Pulmonary Embolism\n26. Subarachnoid hemorrhage\n27. Active intravascular clotting\n28. Major comorbidities\n29. Coronary artery disease (New York Heart Association Class III or IV)\n30. Previous MI\n31. Severe pulmonary disease (FEV \\<50% normal)\n32. Plasma creatinine \\> 115 μmol/L in males, \\> 100 μmol/L in females, or hepatic failure)\n\n34\\. Participation in another clinical trial 35. \\*All women of child bearing potential must have a negative serum or urine pregnancy test.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Total Blood Loss","description":"Total Blood Loss as calculated according to method as described by Good et al. Total Blood Loss (mL) = 1000 X Hb(loss)/Hb(initial)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1122.4","spread":"411.6"},{"groupId":"OG001","value":"1472","spread":"475.4"}]}]}]},{"type":"PRIMARY","title":"Total Hemoglobin Loss","description":"Total hemoglobin loss estimated using the formula for total blood volume described by Nadler et al Hb(loss) = blood volume (L) x \\[Hb(initial)(g/L) - Hb(final)(g/L)\\] + Hb(transfused)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"154.6","spread":null},{"groupId":"OG001","value":"200.1","spread":null}]}]}]},{"type":"PRIMARY","title":"Total Drain Output","description":"Total Drain Output as measured postoperatively 0-48 hours","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"221","spread":null},{"groupId":"OG001","value":"372","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Experiencing Pulmonary Embolism","description":"The occurrence of the following systemic and surgical site complications within 6 weeks of surgery will be recorded. Data will be obtained from EMR and from patient at standard of care 2 week and 6 week follow-up appointment.\n\nPulmonary Embolism","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Experiencing Myocardial Infarction","description":"The occurrence of the following systemic and surgical site complications within 6 weeks of surgery will be recorded. Data will be obtained from EMR and from patient at standard of care 2 week and 6 week follow-up appointment.\n\nMyocardial infarction","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Experiencing Deep Vein Thrombosis","description":"The occurrence of the following systemic and surgical site complications within 6 weeks of surgery will be recorded. Data will be obtained from EMR and from patient at standard of care 2 week and 6 week follow-up appointment.\n\nDeep venous thrombosis","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Experiencing Hematoma as a Surgical Site Complication","description":"The occurrence of the following systemic and surgical site complications within 6 weeks of surgery will be recorded. Data will be obtained from EMR and from patient at standard of care 2 week and 6 week follow-up appointment.\n\nHematoma","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Experiencing Infection as a Surgical Site Complication","description":"The occurrence of the following systemic and surgical site complications within 6 weeks of surgery will be recorded. Data will be obtained from EMR and from patient at standard of care 2 week and 6 week follow-up appointment.\n\nInfection","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":53},"commonTop":["Skin Allergic Reaction","Syncopal fall"]}}}